Cover Image
市場調查報告書

藥物成癮的開發中產品分析

Drug Addiction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251560
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
藥物成癮的開發中產品分析 Drug Addiction - Pipeline Review, H1 2017
出版日期: 2017年03月08日 內容資訊: 英文 165 Pages
簡介

藥癮又稱為「耽溺藥物」,愈是成癮到破壞性的模式,要脫離該藥物就會愈加困難。藥物成癮患者主要的症狀及行動有頻繁使用藥物、不去履行職場·學校·家庭等應該採取的行為、失眠症、睡眠不規則化、異常懶惰感、厭食症/吃得過多症、用餐行為的變化、手掌體溫降低·發汗、手舞足蹈、眼睛充血·眼淚、瞳孔擴張/縮小、呼吸·人體·衣服發出異臭等。

本報告提供全球各國治療藥物成癮用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

藥物成癮概要

治療藥的開發

  • 藥物成癮開發中產品:概要
  • 藥物成癮開發中產品:比較分析

各企業開發中的藥物成癮治療藥

大學/研究機關研究中的藥物成癮治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

藥物成癮治療藥:開發中的產品的一覽(各企業)

藥物成癮治療藥:研究中的產品的一覽(大學/研究機關別)

藥物成癮治療藥的開發企業

  • Gilead Sciences, Inc.
  • Aphios Corporation
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.
  • Biotie Therapies Corp.
  • Camurus AB
  • Curemark, LLC
  • Rottapharm SpA
  • Omeros Corporation
  • Immunovaccine, Inc.
  • 杏林製藥
  • D&A Pharma SAS
  • Embera NeuroTherapeutics, Inc.
  • Lightlake Therapeutics Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • LondonPharma Ltd.

藥物成癮:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • nepicastat hydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ibudilast
  • buprenorphine hydrochloride
  • TV-1380
  • cannabidiol
  • (oxazepam + metyrapone)
  • SKL-N05
  • LT-22
  • ASB
  • methadone
  • GS-6673
  • dronabinol
  • ADX-88178
  • ADX-71441
  • OMS-527
  • Vaccine for Cocaine Addiction
  • Vaccine for Cocaine Addiction
  • MH-6 Vaccine
  • Vaccine for Drug Addiction
  • Ibogaine Analog
  • Small Molecules to Inhibit DAT for Cocaine Addiction and Cocaine Abuse
  • Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders
  • CM-1212
  • methoxycoronaridine
  • Small Molecules to Inhibit BRD for Cancer and Cocaine Dependence
  • CR-5542 Series
  • Small Molecules to Inhibit DAT and SERT for CNS Disorders
  • Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders
  • Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction
  • Small Molecule to Activate Kappa Opioid Receptor for CNS
  • Small Molecule to Inhibit Kappa Opioid Receptor for CNS
  • Drug for Dependence

藥物成癮治療藥:開發中產品的最新趨勢

藥物成癮治療藥:暫停開發的產品

藥物成癮治療藥:中止開發的產品

藥物成癮相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9022IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 6, 2, 28, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Addiction - Overview
  • Drug Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Drug Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aelis Farma SAS
    • Aphios Corp
    • Astraea Therapeutics LLC
    • BioCorRx Inc
    • Cerecor Inc
    • Chiesi Farmaceutici SpA
    • Curemark LLC
    • Embera NeuroTherapeutics Inc
    • F. Hoffmann-La Roche Ltd
    • Foresee Pharmaceuticals LLC
    • Heptares Therapeutics Ltd
    • Immunovaccine Inc
    • Indivior Plc
    • InterveXion Therapeutics LLC
    • Intra-Cellular Therapies Inc
    • Kyorin Pharmaceutical Co Ltd
    • Kyowa Hakko Kirin Co Ltd
    • MedRev Pharma
    • NLS Pharma Group
    • Omeros Corp
    • Opiant Pharmaceuticals Inc
    • Orexigen Therapeutics Inc
    • P2D Bioscience
    • Saniona AB
    • Savant HWP Inc
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd
    • Zynerba Pharmaceuticals Inc
  • Drug Addiction - Drug Profiles
    • (acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile
    • (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile
    • (metyrapone + oxazepam) - Drug Profile
    • 18-MC - Drug Profile
    • ADX-71441 - Drug Profile
    • ADX-71743 - Drug Profile
    • ADX-88178 - Drug Profile
    • AEF-0117 - Drug Profile
    • ANS-6637 - Drug Profile
    • AT-076 - Drug Profile
    • AT-089 - Drug Profile
    • AT-1001 - Drug Profile
    • AT-212 - Drug Profile
    • Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
    • cannabidiol - Drug Profile
    • CERC-501 - Drug Profile
    • CM-1212 - Drug Profile
    • dronabinol - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Dependence - Drug Profile
    • Enzyme for Cocaine Addiction - Drug Profile
    • EORA-101 - Drug Profile
    • FP-004 - Drug Profile
    • Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
    • h2E-2 - Drug Profile
    • ibudilast - Drug Profile
    • istradefylline - Drug Profile
    • ITI-333 - Drug Profile
    • IXT-m200 - Drug Profile
    • JDTic - Drug Profile
    • JQ-1 - Drug Profile
    • KDAC-0001 - Drug Profile
    • levofacetoperane - Drug Profile
    • lofexidine hydrochloride - Drug Profile
    • LT-22 - Drug Profile
    • MC-100093 - Drug Profile
    • naloxone hydrochloride - Drug Profile
    • naltrexone hydrochloride SR - Drug Profile
    • NS-2359 - Drug Profile
    • OMS-405 - Drug Profile
    • OMS-527 - Drug Profile
    • OREX-1019 - Drug Profile
    • OREX-1038 - Drug Profile
    • RBP-8000 - Drug Profile
    • Recombinant Enzyme for Cocaine Abuse - Drug Profile
    • RO-5256390 - Drug Profile
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder and Schizophrenia - Drug Profile
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
    • Small Molecules for Neonatal Abstinence Syndrome - Drug Profile
    • Small Molecules to Agonize 5HT2C and Antagonize 5HT2A, 5HT2B for Psychiatric Disorders - Drug Profile
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
    • Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile
    • Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
    • Vaccine for Cocaine Addiction - Drug Profile
    • Vaccine for Drug Abuse - Drug Profile
    • Vaccine for Methamphetamine Abuse - Drug Profile
    • Vaccine for Methamphetamine Addiction - Drug Profile
    • VU-0463841 - Drug Profile
  • Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Drug Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Drug Addiction - Pipeline by Aelis Farma SAS, H1 2017
  • Drug Addiction - Pipeline by Aphios Corp, H1 2017
  • Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
  • Drug Addiction - Pipeline by BioCorRx Inc, H1 2017
  • Drug Addiction - Pipeline by Cerecor Inc, H1 2017
  • Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Drug Addiction - Pipeline by Curemark LLC, H1 2017
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
  • Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Drug Addiction - Pipeline by Immunovaccine Inc, H1 2017
  • Drug Addiction - Pipeline by Indivior Plc, H1 2017
  • Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2017
  • Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2017
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Drug Addiction - Pipeline by MedRev Pharma, H1 2017
  • Drug Addiction - Pipeline by NLS Pharma Group, H1 2017
  • Drug Addiction - Pipeline by Omeros Corp, H1 2017
  • Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
  • Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
  • Drug Addiction - Pipeline by P2D Bioscience, H1 2017
  • Drug Addiction - Pipeline by Saniona AB, H1 2017
  • Drug Addiction - Pipeline by Savant HWP Inc, H1 2017
  • Drug Addiction - Pipeline by Stada Arzneimittel AG, H1 2017
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Drug Addiction - Dormant Projects, H1 2017
  • Drug Addiction - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Drug Addiction - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Drug Addiction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Drug Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top